Platelet inhibition and bleeding complications in cardiac surgery: A review

Scandinavian Cardiovascular Journal

Volumn 50, Issue 5-6, 2016, Pages 349-354

  Hansson, Emma C ^a,b   Jeppsson, Anders ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

bleeding; cardiac surgery; platelet inhibition; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; DRUG EFFECT; DUAL ANTIPLATELET THERAPY; HEART SURGERY; HUMAN; MORBIDITY; MORTALITY; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE FUNCTION; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; OPERATIVE BLOOD LOSS; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ASPIRIN; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84992411638     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017431.2016.1231935     Document Type: Review

References (49)

1. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass:a review. Intensive Care Med. 2004;30:1873–1881.
2. Dyke C, Aronson S, Dietrich W, et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg. 2014;147:1458–1463.e1.
3. Stone GW, Clayton TC, Mehran R, et al. Impact of major bleeding and blood transfusions after cardiac surgery:analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Am Heart J. 2012;163:522–529.
4. Dixon B, Santamaria JD, Reid D, et al. The association of blood transfusion with mortality after cardiac surgery:cause or confounding? (CME). Transfusion. 2013;53:19–27.
5. Ranucci M, Bozzetti G, Ditta A, et al. Surgical reexploration after cardiac operations:why a worse outcome? Ann Thorac Surg. 2008;86:1557–1562.
6. Vivacqua A, Koch CG, Yousuf AM, et al. Morbidity of bleeding after cardiac surgery:is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg. 2011;91:1780–1790.
7. Frojd V, Jeppsson A. Reexploration for bleeding and its association with mortality after cardiac surgery. Ann Thorac Surg. 2016;102:109–117.
8. Mehta RH, Sheng S, O'Brien SM, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery:incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes. 2009;2:583–590.
9. Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037–1046.
10. Surgenor SD, Kramer RS, Olmstead EM, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg. 2009;108:1741–1746.
11. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015;372:997–1008.
12. Roffi M, Patrono C, Collet JP, et al. 2015 ESC *Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the. European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.
13. Task Force on the Management of STseamiotESoC, Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
14. Patrono C. Aspirin A2. In:Michelson, Alan D, editors. Platelets. 3rd ed. New York:Academic Press; 2013. p. 1099–1115 (Chapter 53).
15. Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery:a systematic review and meta-analysis. Br J Anaesth. 2015;115:376–385.
16. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990;82:17–26.
17. Yusuf S, Zhao F, Mehta SR, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
18. Wallentin L. P2Y(12) inhibitors:differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30:1964–1977.
19. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
20. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
21. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort:risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60:388–396.
22. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
23. Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015;125:3484–3490.
24. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933–2944.
25. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery:results from the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol. 2011;57:672–684.
26. Hansson EC, Jideus L, Aberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel:a nationwide study. Eur Heart J. 2016;37:189–197.
27. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–2619.
28. Myles PS, Smith JA, Forbes A, et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med. 2016;374:728–737.
29. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986–1990.
30. Deja MA, Kargul T, Domaradzki W, et al. Effects of preoperative aspirin in coronary artery bypass grafting:a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg. 2012;144:204–209.
31. Hansson EC, Shams Hakimi C, Astrom-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth. 2014;112:570–575.
32. Martin AC, Berndt C, Calmette L, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation:an in-vitro study. Eur J Anaesthesiol. 2016;33:361–367.
33. O'Connor SA, Amour J, Mercadier A, et al. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor:the APTITUDE study. Circ Cardiovasc Interv. 2015;8:e002786.
34. Fox KA, Mehta SR, Peters R, et al. Clopidogrel in unstable angina to prevent Recurrent ischemic Events T. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202–1208.
35. Tomsic A, Schotborgh MA, Manshanden JS, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothor Surg. 2016 (Epub ahead of print).
36. Kedhi E, Stone GW, Kereiakes DJ, et al. Stent thrombosis:insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. Eurointervention. 2012;8:599–606.
37. Malm C, Hansson EC, Åkesson J, et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients. Br J Anaesth. 2016;117:309–315.
38. Mangano DT, Multicenter Study of Perioperative Ischemia Research G. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309–1317.
39. Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting:is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013;28:109–116.
40. Verma S, Goodman SG, Mehta SR, et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg. 2015;15:112.
41. Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost. 2011;9:1730–1737.
42. Born GV, Cross MJ. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature. 1963;197:974–976.
43. Corredor C, Wasowicz M, Karkouti K, et al. The role of point-of-care platelet function testing in predicting postoperative bleeding following cardiac surgery:a systematic review and meta-analysis. Anaesthesia. 2015;70:715–731.
44. Plicner D, Mazur P, Hymczak H, et al. Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery. Thromb Res. 2015;136:519–525.
45. Ranucci M, Baryshnikova E, Soro G, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg. 2011;91:123–129.
46. Ranucci M, Colella D, Baryshnikova E, et al. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth. 2014;113:970–976.
47. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery:the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012;5:261–269.
48. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
49. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery:a randomized controlled trial. J Am Med Assoc. 2012;307:265–274.